Efficacy of Mirabegron, Solifenacin, Tamsulosine, Tadalafil and Their Combinations in the Treatment of Double-J Stent-Related Lower Urinary Tract Symptoms

Phase 3

Completed

• Conditions: Patients with Double-J Stent-Related Lower Urinary Tract Symptoms.; Double-J Stent; Lower Urinary Tract Symptoms; Ureteral Stent Symptoms Questionnaire

• Registration Number: TCTR20221014002
• Lead Sponsor: Muhammad Asykar Palinrungi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-09-30
• Study Start: 2022-10-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 161

Inclusion Criteria

Inclusion criterias are willing to undergo voluntary research, age 18 to 79 years old, has indications of endoscopic ureteral stent insertion, is diagnosed with ureteral stones less than 10 mm (with or without dilatation of pelvic, calix, ureter), ureteral stenosis, and or kidney stones and will undergo shockwave lithotripsy (ESWL), has had the first insertion of ureteral stent, and has indications for the unilateral ureteral stent insertion.

Exclusion Criteria

Exclusion criterias are history of malignancy in the urinary tract, history of hypertrophic prostate, history of previous sexual dysfunction, having had a urinary tract infections in the previous 6 months, pregnancy, history of diabetes mellitus, cardiovascular disease, or hypertension, having or undergoing radiation therapy, hormonal therapy, and or minor pelvic surgical procedures, previous surgery of ureteral reconstruction, history of alcoholism, history of stroke, having Alzheimers disease, having central nervous system trauma, having accompanying stones in the bladder, history of urethra diverticula in women, and hypersensitivity to Tadalafil or Tamsulosin or Mirabegron or Solifenacin.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
treatment outcomes The Ureteral Stent Symptoms Questionnaire (USSQ) was used to compare treatment outcomes was measured 4 weeks after treatments. The Ureteral Stent Symptoms Questionnaire (USSQ)

Secondary Outcome Measures

Name	Time	Method
demography data when the subject willing to undergo voluntary research age and gender